Mutation of TCF2 has been observed in renal cell cancer, and by screening aberrantly methylated genes, we have now identified TCF2 as a target for epigenetic inactivation in ovarian cancer. The gene discussed is HNF1B; the disease is renal cell adenocarcinoma.